Winning week despite Friday's slide | Latest on Trump's health | Waiting for stimulus

The S&P 500 managed to only dip less than 1% Friday and ended the week with a gain of 1.5%.

VIEW IN BROWSER | SUBSCRIBE SAT, OCT 03, 2020 WEEKEND BRIEF EDITOR'S NOTE First, there was the shocking news that President Donald Trump tested positive for coronavirus, then a disappointing September jobs report. Yet the S&P 500 managed to only dip less than 1% Friday and ended the week with a gain of 1.5%.   Some say that's because investors chose to latch onto the silver lining from this double-whammy: It could serve as a catalyst to break the stalemate in Washington on further coronavirus stimulus.   There were some signs of progress on a deal on Friday. House Speaker Nancy Pelosi called on airlines to halt furloughs, promising some "imminent" aid either as part of a bi-partisan standalone bill or as part of a bigger negotiated relief bill.   "The stock market seems like it was glued to that stimulus," said Jim Paulsen, chief investment strategist at Leuthold Group. "It would swing back and forth on it. The stimulus package matters."   Still, Trump's diagnosis just one month before the election made the stakes a lot higher for investors who have already been on edge about how different outcomes would impact the markets.   In the week ahead, traders will be on high alert for updates on Trump's health as well as the ongoing fiscal stimulus fight. Federal Reserve Chair Jerome Powell is scheduled to give a speech to the National Association of Business Economists on Tuesday.   Powell is expected to discuss the need for fiscal stimulus to stop the economic recovery from faltering after the weak jobs report.   Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world. Yun Li | CNBC Markets and Investing Reporter @YunLi626 THE WEEK AHEAD Trump's health and fiscal stimulus fight will steer the markets in the week ahead   YOUR WEEKEND BRIEFING  Trump 'doing very well,' has started Remdesivir therapy, White House physician says What we know—and don't know—about the president's coronavirus diagnosis so far Here's everything we know about the unapproved antibody drug Trump took to combat coronavirus Wall Street analysts see long-term share gains for stocks like Costco and Redfin 'Massively concerning' jobs report sends a signal that the economic recovery could be fading Here are JPMorgan's best stock ideas for October     Unsubscribe Manage Newsletters Terms of Service Join the CNBC Panel Digital Products Feedback Privacy Policy   © 2020 CNBC LLC. All rights reserved. A property of NBCUniversal. 900 Sylvan Avenue, Englewood Cliffs, NJ 07632 Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis. Data also provided by THOMSON REUTERS